Table 1.
Baseline clinical characteristics of the study cohort
| Con |
MetS |
|||
|---|---|---|---|---|
| Non-RT (n = 12) |
RT (n = 16) |
Non-RT (n = 16) |
RT (n = 13) |
|
| Age (years) | 44 ± 3 | 49 ± 3 | 51 ± 4 | 51 ± 3 |
| Height (cm) | 166 ± 2 | 166 ± 2 | 168 ± 2 | 166 ± 2 |
| Weight (kg) | 68 ± 4 | 67 ± 3 | 95 ± 6* | 87 ± 4* |
| Body fat (%) | 23 ± 3 | 26 ± 2 | 38 ± 2* | 38 ± 2* |
| BMI (kg/m2) | 24 ± 1 | 24 ± 0.9 | 33 ± 2* | 32 ± 1* |
| Sex (% female) | 75 | 75 | 73 | 69 |
| Waist (cm) | 82 ± 4 | 82 ± 2 | 105 ± 3* | 97 ± 3* |
| Hip (cm) | 100 ± 3 | 100 ± 1 | 117 ± 3* | 112 ± 2* |
| Triglycerides (mmol/l) | 1.0 ± 0.1 | 0.6 ± 0.1 | 1.7 ± 0.2* | 1.7 ± 0.4* |
| HDL (mmol/l) | 1.4 ± 0.1 | 1.7 ± 0.3 | 1.1 ± 0.1* | 1.2 ± 0.1* |
| Glucose (mmol/l) | 5.3 ± 0.2 | 5.1 ± 0.2 | 5.5 ± 0.1* | 5.6 ± 0.2* |
| HbA1c (%) | 5.3 ± 0.1 | 5.1 ± 0.1 | 5.7 ± 0.1* | 5.2 ± 0.1# |
| Cholesterol (mmol/l) | 5.1 ± 0.3 | 4.6 ± 0.2 | 4.7 ± 0.3 | 5.1 ± 0.3 |
| Hypertensive (%) | 0 | 0 | 44 | 46 |
| Diabetics (%) | 0 | 0 | 0 | 0 |
| Medications | ||||
| ACE inhibitors (%) | 0 | 0 | 13 | 0 |
| ARB (%) | 0 | 0 | 13 | 8 |
| Beta-blockers (%) | 0 | 0 | 6 | 15 |
| Calcium channel blockers (%) |
0 | 0 | 6 | 0 |
| Diuertics (%) | 0 | 0 | 13 | 15 |
| Anti-platelet (%) | 0 | 0 | 0 | 0 |
| Statin (%) | 0 | 0 | 19 | 23 |
Values are mean ± SEM
BMI body mass index, HDL high-density lipoprotein, HbA1c hemoglobin A1c, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker
*
Denotes p ≤ 0.05 compared to both Con groups
#
Denotes significant within group effects